- AnaptysBio ( NASDAQ: ANAB ) said it had authorized a stock repurchase plan under which it can repurchase up to $50M common stock for $0.001 per share.
- ( ANAB ) rose ~10% .
- The company also reiterated its guidance that it expects having about 4 years of capital to execute against its non-risk adjusted research and development plan, excluding potential future royalties from its GSK immuno-oncology financial collaboration.
- The company has cash of more than $575M as of December 31.
- The Stock Repurchase Plan will expire on Dec. 31, 2023, and could be suspended or discontinued at any time. it added.
For further details see:
AnaptysBio rises 10% on stock repurchase of up to $50M